As of 2025-05-31, the Intrinsic Value of Zhende Medical Co Ltd (603301.SS) is 12.50 CNY. This 603301.SS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 20.83 CNY, the upside of Zhende Medical Co Ltd is -40.00%.
The range of the Intrinsic Value is 9.93 - 17.52 CNY
Based on its market price of 20.83 CNY and our intrinsic valuation, Zhende Medical Co Ltd (603301.SS) is overvalued by 40.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 9.93 - 17.52 | 12.50 | -40.0% |
| DCF (Growth 10y) | 16.08 - 29.26 | 20.57 | -1.3% |
| DCF (EBITDA 5y) | 96.56 - 132.44 | 120.85 | 480.2% |
| DCF (EBITDA 10y) | 105.75 - 161.38 | 139.21 | 568.3% |
| Fair Value | 34.06 - 34.06 | 34.06 | 63.52% |
| P/E | 39.61 - 52.78 | 46.54 | 123.4% |
| EV/EBITDA | 34.29 - 53.15 | 45.01 | 116.1% |
| EPV | (7.28) - (9.31) | (8.30) | -139.8% |
| DDM - Stable | 9.29 - 22.91 | 16.10 | -22.7% |
| DDM - Multi | 19.25 - 35.84 | 24.94 | 19.8% |
| Market Cap (mil) | 5,550.15 |
| Beta | 0.99 |
| Outstanding shares (mil) | 266.45 |
| Enterprise Value (mil) | 5,569.98 |
| Market risk premium | 6.13% |
| Cost of Equity | 11.31% |
| Cost of Debt | 5.00% |
| WACC | 10.61% |